



Neuland Laboratories Limited

Sanali Info Park, 'A' Block,
Ground Floor, 8-2-120/113
Road No. 2, Banjara Hills
Hyderabad - 500 034.
Telangana, India.

Tel: 040 30211600 / 23551081

Fax: 040 30211602

Email: neuland@neulandlabs.com

www.neulandlabs.com

May 12, 2021

To
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400 001

To
The National Stock Exchange of India Ltd
Exchange Plaza,
Bandra Kurla Complex, Bandra (E)
Mumbai - 400 001

Scrip Code: 524558

Scrip Code: NEULANLAB; Series: EQ

Dear Sirs,

Sub: Compliance with Regulation 47(1)(b) of the SEBI Listing Regulations, 2015

Please find attached herewith copies of the newspaper publication of Audited Financial Results for the quarter and year ended March 31, 2021, published in Financial Express and Andhra Prabha on May 12, 2021 for your reference.

This is for your information and records.

Yours faithfully,

For **Neuland Laboratories Limited**

Sarada Bhamidipati
Company Secretary

Encl: As above



NEULAND LABORATORIES LIMITED (CIN : L85195TG1984PLC004393) Regd. office: Sanali Info park, 'A' Block, Ground floor 8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034 NEULAND					
EXTRACT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2021 (Amount in lakhs of ₹, unless otherwise stated)					
Sl. No.	Particulars	Quarter Ended 31.03.2021	Quarter Ended 31.03.2020	Year Ended 31.03.2021	Year Ended 31.03.2020
1	Revenue from operations	24,470.47	19,164.19	93,691.31	76,271.08
2	Net profit for the period before tax	2,439.01	1,719.80	10,533.35	5,292.25
3	Net profit for the period after tax	1,729.26	(929.57)	8,063.07	1,621.05
4	Total comprehensive income for the period	1,580.93	(894.50)	7,906.60	1,577.65
5	Paid-up Equity Share Capital (Face value - ₹10 each)	1,290.05	1,290.05	1,290.05	1,290.05
6	Other equity (excluding revaluation reserves) as shown in the audited balance sheet	77,271.83	69,621.83	77,271.83	69,621.83
7	Earnings Per Share (of ₹10 each) (In absolute ₹ terms)	As at 31.03.2021	As at 31.03.2020	As at 31.03.2021	As at 31.03.2020
	(a) Basic	13.48	(7.25)	62.85	12.63
	(b) Diluted	13.48	(7.25)	62.85	12.63

Note 1: The financial results for the quarter and year ended 31 March 2021 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 11 May 2021.

Note 2: Key Standalone Financial Information:

Particulars	Quarter Ended 31.03.2021	Quarter Ended 31.03.2020	Year Ended 31.03.2021	Year Ended 31.03.2020
Revenue from operations	24,470.47	19,186.59	93,691.31	76,271.08
Net profit for the period before tax	2,431.59	1,707.68	10,496.21	5,249.58
Net profit for the period after tax	1,722.80	(935.00)	8,029.49	1,588.01

Note 3: The above is an extract of the detailed format of Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.neulandlabs.com

By Order of the Board
For Neuland Laboratories Limited
Dr. D.R.Rao
Executive Chairman
(DIN 00107737)

Place: Hyderabad
Date : 11 May 2021

NEULAND LABORATORIES LIMITED (CIN : L85195TG1984PLC004393) Regd. office: Sanali Info park, 'A' Block, Ground floor 8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034 NEULAND					
EXTRACT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2021 (Amount in lakhs of ₹, unless otherwise stated)					
Sl. No.	Particulars	Quarter Ended 31.03.2021	Quarter Ended 31.03.2020	Year Ended 31.03.2021	Year Ended 31.03.2020
1	Revenue from operations	24,470.47	19,164.19	93,691.31	76,271.08
2	Net profit for the period before tax	2,439.01	1,719.80	10,533.35	5,292.25
3	Net profit for the period after tax	1,729.26	(929.57)	8,063.07	1,621.05
4	Total comprehensive income for the period	1,580.93	(894.50)	7,906.60	1,577.65
5	Paid-up Equity Share Capital (Face value - ₹10 each)	1,290.05	1,290.05	1,290.05	1,290.05
6	Other equity (excluding revaluation reserves) as shown in the audited balance sheet	77,271.83	69,621.83	77,271.83	69,621.83
7	Earnings Per Share (of ₹10 each) (In absolute ₹ terms)	As at 31.03.2021	As at 31.03.2020	As at 31.03.2021	As at 31.03.2020
	(a) Basic	13.48	(7.25)	62.85	12.63
	(b) Diluted	13.48	(7.25)	62.85	12.63

Note 1: The financial results for the quarter and year ended 31 March 2021 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 11 May 2021.

Note 2: Key Standalone Financial Information:

Particulars	Quarter Ended 31.03.2021	Quarter Ended 31.03.2020	Year Ended 31.03.2021	Year Ended 31.03.2020
Revenue from operations	24,470.47	19,186.59	93,691.31	76,271.08
Net profit for the period before tax	2,431.59	1,707.68	10,496.21	5,249.58
Net profit for the period after tax	1,722.80	(935.00)	8,029.49	1,588.01

Note 3: The above is an extract of the detailed format of Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.neulandlabs.com

By Order of the Board
For Neuland Laboratories Limited
Dr. D.R.Rao
Executive Chairman
(DIN 00107737)

Place: Hyderabad
Date : 11 May 2021